ArticleScientific reports2026
Eco-friendly spectrophotometric approach for the determination of anti-diabetic drugs in fixed-dose formulation together with metformin's toxic impurity: comprehensive method assessment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Environmentally benign and straightforward spectrophotometric methods were developed and validated for the simultaneous determination of saxagliptin (SAX), metformin (MET), and the pharmacopeial impurity of MET, melamine (MEL), in bulk powder and pharmaceutical formulations. These proposed approaches provide reliable, low-cost, and accessible alternatives to conventional chromatographic techniques, which often require complex instrumentation, extended analysis times, and significant solvent consumption. Two complementary spectrophotometric methods were established. Method A, the ratio-difference approach, utilized MEL as a divisor for the quantification of SAX, while SAX served as a divisor for determining MET and MEL. Method B, based on the first derivative of ratio spectra, applied MEL as a divisor under optimized conditions (scaling factor = 10, Δλ = 4 nm). However, MEL could not be quantified by Method B because its derivative ratio signals in the selected spectral region were too weak and overlapped extensively with those of SAX and MET, preventing the establishment of a reliable linear calibration curve for this impurity. The methods exhibited linearity over the ranges of 5-90 µg/mL for SAX, 1-40 µg/mL for MET, and 0.5-10 µg/mL for MEL. Validation in accordance with ICH Q2(R1) guidelines confirmed their accuracy, precision, selectivity, and specificity. The results obtained by the proposed methods were statistically compared with those of a reported RP‑HPLC method, confirming the reliability of the proposed procedures. The environmental impact was assessed using the principles of green analytical chemistry (GAC), which incorporates sustainability by promoting methods that limit hazardous reagents, reduce energy consumption, and minimize waste while maintaining suitable analytical performance. Holistic evaluation tools such as the analytical greenness metric (AGREE), the green analytical procedure index (GAPI), the national environmental methods index (NEMI), the blue applicability grade index (BAGI), and the RGB 12 model enable simultaneous assessment of analytical quality, environmental impact, and practical applicability. These tools foster the development of "white" analytical chemistry and complement emerging indices like the environmental and practical performance index (EPPI).Overall, these spectrophotometric approaches represent sustainable, efficient, and accessible analytical alternatives for the routine quality control of Saxagliptin and Metformin in combined pharmaceutical formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.